Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Isatuximab and Cemiplimab in Relapsed or Refractory Natural Killer/T-cell Lymphoid Malignancy : Nick Name - ICING Study

NCT04763616 is registered in ClinicalTrials.gov with Won Seog Kim as lead sponsor.

NCT NCT04763616
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04763616 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Isatuximab and Cemiplimab in Relapsed or Refractory Natural Killer/T-cell Lymphoid Malignancy : Nick Name - ICING Study
Lead sponsor
Won Seog Kim
Phase
Phase 2
Overall status
Completed
Start date
June 25, 2021
Completion date
April 1, 2026
Enrollment
37 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

natural killer/t-cell lymphoma, refractory natural killer/t-cell lymphoma, relapsed natural killer/t-cell lymphoma